N/A
Completed N=113
Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Untreated CD30-Positive Hodgkin's Lymphoma"
Source: ClinicalTrials.gov NCT03729609 ↗Enrolled (actual)
113
Serious AEs
39.3%
Results posted
Aug 2024
Primary outcomePrimary: Percentage of Participants With Grade 3 or Higher Neutropenia and Febrile Neutropenia — 65; 31 Participants
Summary
The purpose of this survey is to monitor and identify the occurrence of neutropenia and febrile neutropenia in untreated CD30-positive Hodgkin's lymphoma participants on concomitant brentuximab vedotin and doxorubicin hydrochloride, vinblastine sulfate, and dacarbazine (AVD) in routine clinical practice.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Participants With Grade 3 or Higher Neutropenia and Febrile Neutropenia |
65; 31 | — |
| SECONDARY Tumor Response Rate Based on Investigator's Assessment |
87 | — |
Eligibility Criteria
Inclusion Criteria
- Untreated participants
- CD30-positive participants
- Participants on concomitant Brentuximab vedotin and AVD
Exclusion Criteria
- Participants contraindicated for Brentuximab vedotin
Data sourced from ClinicalTrials.gov (NCT03729609). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.